跳转至内容
Merck
CN

SML4064

Ac-Abu-Tle-Leu-Gln-AFC

≥95% (HPLC)

别名:

Ac-Abu-Tle-LQ-AFC (Abu=2-Aminobutyrate, Tle=t-Butylglycine, AFC = 4-trifluoromethylcoumaryl-7-amide), Ac-QS1-AFC, Acetyl-L-α-aminobutyroyl-L-tert-leucyl-L-leucyl-L-glutamine-α-(4-trifluoromethylcoumaryl-7-amide)

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C34H46F3N5O8
分子量:
709.75
NACRES:
NA.21
Assay:
≥95% (HPLC)
Form:
(Powder or Lyophilized powder or film)
Quality level:
100
Storage condition:
desiccated

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C34H46F3N5O8/c1-8-23(39-18(4)43)31(48)42-29(33(5,6)7)25(44)14-19(13-17(2)3)30(47)41-24(11-12-27(38)45)32(49)40-20-9-10-21-22(34(35,36)37)16-28(46)50-26(21)15-20/h9-10,15-17,19,23-24,29H,8,11-14H2,1-7H3,(H2,38,45)(H,39,43)(H,40,49)(H,41,47)(H,42,48)/t19

InChI key

VWVFVJSQWAXHGY-RYRALHHHSA-N

SMILES string

CC(N[C@H](C(N[C@H](C(C[C@H](C(N[C@H](C(NC1=CC2=C(C=C1)C(C(F)(F)F)=CC(O2)=O)=O)CCC(N)=O)=O)CC(C)C)=O)C(C)(C)C)=O)CC)=O

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

Quality Level

100

Biochem/physiol Actions

Kinetically preferred fluorogenic substrate for detecting SARS-CoV and SARS-CoV-2 main proteases (Mpro; 3CLpro) activity (ex 380+/-20 nm, em 500+/-20 nm).
Ac-QS1-AFC or Ac-Abu-Tle-Leu-Gln-AFC (Abu = Aminobutyrate; Tle = t-Butylglycine; AFC= 7-amino-4-trifluoromethyl coumarin) is a kinetically preferred fluorogenic substrate for the detection of SARS-CoV and SARS-CoV-2 main protease (Mpro; 3CLpro) activity. Mpro cleavage results in the release of the C-terminal AFC and increased fluorescence (ex 380+/-20 nm, em 500+/-20 nm).

Disclaimer

Hygroscopic

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000393391
0000393388
0000393391
0000393388

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
PLoS ONE, 16(2) (2021)
Wioletta Rut et al.
Nature chemical biology, 17(2), 222-228 (2020-10-24)
In December 2019, the first cases of infection with a novel coronavirus, SARS-CoV-2, were diagnosed. Currently, there is no effective antiviral treatment for COVID-19. To address this emerging problem, we focused on the SARS-CoV-2 main protease that constitutes one of

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持